Your browser is no longer supported. Please, upgrade your browser.
Inventiva S.A.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand38.63M Perf Week4.44%
Market Cap517.65M Forward P/E- EPS next Y- Insider Trans- Shs Float10.21M Perf Month-1.69%
Income- PEG- EPS next Q- Inst Own6.23% Short Float1.77% Perf Quarter-5.50%
Sales4.54M P/S113.92 EPS this Y- Inst Trans- Short Ratio4.51 Perf Half Y0.07%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-4.35%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range10.52 - 19.06 Perf YTD-7.59%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.71% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low27.38% ATR0.49
Employees95 Current Ratio- Sales Q/Q-76.10% Oper. Margin- RSI (14)48.87 Volatility2.79% 3.17%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.20 Prev Close13.65
ShortableNo LT Debt/Eq- EarningsSep 20 AMC Payout- Avg Volume40.11K Price13.40
Recom- SMA20-2.67% SMA504.13% SMA200-5.42% Volume8,113 Change-1.87%
Mar-08-21Downgrade Societe Generale Buy → Sell
Aug-05-20Initiated ROTH Capital Buy
Aug-04-20Initiated Stifel Buy $18
Aug-04-20Initiated Guggenheim Buy $26
Sep-28-21 04:00PM  
Sep-23-21 02:45AM  
Sep-22-21 07:01AM  
Sep-21-21 04:00PM  
Sep-20-21 04:10PM  
Sep-16-21 04:00PM  
Sep-10-21 09:00AM  
Sep-08-21 04:00PM  
Aug-30-21 04:00PM  
Aug-02-21 05:00PM  
Jul-28-21 04:00PM  
Jul-22-21 10:00AM  
Jun-15-21 04:00PM  
Jun-09-21 04:00PM  
May-25-21 04:00PM  
May-12-21 04:00PM  
Apr-26-21 04:00PM  
Apr-19-21 04:00PM  
Mar-25-21 01:00PM  
Mar-15-21 05:00PM  
Mar-05-21 11:45AM  
Mar-04-21 04:00PM  
Feb-25-21 04:00PM  
Feb-24-21 04:00PM  
Feb-23-21 04:00PM  
Feb-11-21 04:00PM  
Jan-15-21 11:45AM  
Jan-06-21 04:00PM  
Jan-05-21 04:00PM  
Dec-07-20 11:18PM  
Nov-24-20 04:00PM  
Nov-12-20 04:00PM  
Nov-10-20 04:00PM  
Nov-09-20 04:00PM  
Nov-05-20 04:00PM  
Nov-02-20 04:00PM  
Oct-28-20 05:00PM  
Oct-19-20 04:00PM  
Oct-12-20 04:00PM  
Oct-05-20 04:00PM  
Sep-24-20 12:15PM  
Sep-17-20 06:00AM  
Sep-16-20 04:00PM  
Sep-09-20 11:45AM  
Aug-12-20 11:45AM  
Aug-10-20 11:45AM  
Jul-24-20 06:12PM  
Jul-15-20 02:40PM  
Jul-10-20 08:30AM  
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.